• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Pre-Market Session

    3/18/24 9:05:55 AM ET
    $APDN
    $BPTS
    $DBVT
    $ELTX
    Other Consumer Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APDN alert in real time by email

    Gainers

    • Applied DNA Sciences (NASDAQ:APDN) stock moved upwards by 33.1% to $0.49 during Monday's pre-market session. The market value of their outstanding shares is at $8.3 million.
    • XTL Biopharmaceuticals (NASDAQ:XTLB) shares increased by 19.31% to $1.05. The market value of their outstanding shares is at $5.7 million.
    • 2seventy bio (NASDAQ:TSVT) shares rose 17.7% to $4.72. The company's market cap stands at $242.1 million.
    • DBV Technologies (NASDAQ:DBVT) shares moved upwards by 13.92% to $0.9. The company's market cap stands at $173.1 million.
    • Elicio Therapeutics (NASDAQ:ELTX) shares increased by 13.2% to $5.66. The market value of their outstanding shares is at $54.3 million.
    • Moleculin Biotech (NASDAQ:MBRX) stock rose 12.53% to $0.56. The company's market cap stands at $18.5 million.

    Losers

    • Titan Pharma (NASDAQ:TTNP) shares declined by 18.2% to $7.6 during Monday's pre-market session. The market value of their outstanding shares is at $5.7 million.
    • Biophytis (NASDAQ:BPTS) stock fell 14.6% to $0.41. The market value of their outstanding shares is at $3.9 million.
    • Molecular Templates (NASDAQ:MTEM) shares decreased by 14.19% to $2.36. The company's market cap stands at $12.6 million.
    • Nanobiotix (NASDAQ:NBTX) shares fell 9.36% to $6.3. The market value of their outstanding shares is at $296.8 million.
    • TC BioPharm (Holdings) (NASDAQ:TCBP) stock fell 8.92% to $1.53. The company's market cap stands at $3.7 million.
    • Trxade Health (NASDAQ:MEDS) shares decreased by 8.82% to $26.26. The company's market cap stands at $31.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $APDN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APDN
    $BPTS
    $DBVT
    $ELTX

    CompanyDatePrice TargetRatingAnalyst
    Nanobiotix S.A.
    $NBTX
    2/6/2026Buy
    TD Cowen
    DBV Technologies S.A.
    $DBVT
    12/15/2025$42.00Overweight
    Cantor Fitzgerald
    DBV Technologies S.A.
    $DBVT
    12/3/2025$35.00Buy
    Guggenheim
    Moleculin Biotech Inc.
    $MBRX
    6/9/2025$4.00Buy
    H.C. Wainwright
    DBV Technologies S.A.
    $DBVT
    5/29/2025$7.25Sell
    Goldman
    Moleculin Biotech Inc.
    $MBRX
    2/12/2025Buy → Hold
    Maxim Group
    Nanobiotix S.A.
    $NBTX
    8/28/2024$12.00Buy
    Guggenheim
    2seventy bio Inc.
    $TSVT
    6/6/2024$5.00 → $2.00Neutral → Sell
    Goldman
    More analyst ratings

    $APDN
    $BPTS
    $DBVT
    $ELTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on Nanobiotix

    TD Cowen initiated coverage of Nanobiotix with a rating of Buy

    2/6/26 8:11:18 AM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on DBV Technologies with a new price target

    Cantor Fitzgerald initiated coverage of DBV Technologies with a rating of Overweight and set a new price target of $42.00

    12/15/25 9:59:53 AM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on DBV Technologies with a new price target

    Guggenheim initiated coverage of DBV Technologies with a rating of Buy and set a new price target of $35.00

    12/3/25 8:16:35 AM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APDN
    $BPTS
    $DBVT
    $ELTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting

    Châtillon, France, February 28, 2026 DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting Approximately 83% of children treated with the VIASKIN® Peanut Patch increased their eliciting dose at month 12, compared to approximately 48% in the placebo groupApproximately 60% of children treated with the VIASKIN® Peanut Patch increased their eliciting dose by at least two doses at month 12, compared to 23% in the placebo group24% of children on placebo decreased their eliciting dose between the baseline and month 12 double-blind, placebo-controlled food challenge, compared to only 6.4% of children treated with the VIASKIN® Peanut Pat

    2/28/26 2:25:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing

    RAMAT GAN, ISRAEL, Feb. 27, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced today that it has received a letter (the "Letter") from The Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq"), dated February 25, 2026, notifying the Company of the Staff's belief, based upon its review of the Company and pursuant to Nasdaq Listing Rule 5101, that the Company is a "public shell", and that continued listing of the Company's American Depositary Shares ("ADSs") is no longer warranted. The Company intends to request a hearing (the "Hearing") to appeal the delisting process before a Nasdaq Heari

    2/27/26 4:30:00 PM ET
    $XTLB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NANOBIOTIX to Participate in Investor Conferences in March

    PARIS and CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ:NBTX - the "Company"), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in these upcoming conferences in March: TD Cowen's Health Care ConferenceDate: Wednesday, March 4, 2026Location: Boston, MATime of the fireside chat: 11:10am ET / 5:10pm CETPresenters: Laurent Levy, Chief Executive Officer of Nanobiotix and Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix UBS Biotech Summit Miami Date: Monday, March

    2/25/26 4:15:00 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APDN
    $BPTS
    $DBVT
    $ELTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO, President and Director Connelly Robert was granted 73,600 shares, increasing direct ownership by 157% to 120,570 units (SEC Form 4)

    4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

    2/3/26 4:42:10 PM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Shah Preetam was granted 24,000 shares (SEC Form 4)

    4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

    2/3/26 4:40:15 PM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Demuth Peter was granted 20,800 shares, increasing direct ownership by 2,799% to 21,543 units (SEC Form 4)

    4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

    2/3/26 4:38:38 PM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APDN
    $BPTS
    $DBVT
    $ELTX
    SEC Filings

    View All

    Amendment: SEC Form S-3/A filed by Elicio Therapeutics Inc.

    S-3/A - Elicio Therapeutics, Inc. (0001601485) (Filer)

    3/2/26 4:05:36 PM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by DBV Technologies S.A.

    8-K - DBV Technologies S.A. (0001613780) (Filer)

    3/2/26 7:54:26 AM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.

    6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)

    2/27/26 4:34:26 PM ET
    $XTLB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APDN
    $BPTS
    $DBVT
    $ELTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Foster Jonathan P. covered exercise/tax liability with 1,715 shares, bought $100,000 worth of shares (270,270 units at $0.37) and converted options into 7,039 shares, increasing direct ownership by 2,298% to 287,587 units (SEC Form 4)

    4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

    6/23/25 4:35:31 PM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and President Klemp Walter V bought $250,000 worth of shares (675,675 units at $0.37), converted options into 12,740 shares and covered exercise/tax liability with 3,104 shares, increasing direct ownership by 1,176% to 743,607 units (SEC Form 4)

    4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

    6/23/25 4:35:11 PM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biotech Target N V bought $587,500 worth of shares (250,000 units at $2.35), increasing direct ownership by 24% to 1,279,820 units (SEC Form 4)

    4 - Molecular Templates, Inc. (0001183765) (Issuer)

    4/4/24 8:13:35 PM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APDN
    $BPTS
    $DBVT
    $ELTX
    Leadership Updates

    Live Leadership Updates

    View All

    XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing

    RAMAT GAN, ISRAEL, Feb. 27, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced today that it has received a letter (the "Letter") from The Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq"), dated February 25, 2026, notifying the Company of the Staff's belief, based upon its review of the Company and pursuant to Nasdaq Listing Rule 5101, that the Company is a "public shell", and that continued listing of the Company's American Depositary Shares ("ADSs") is no longer warranted. The Company intends to request a hearing (the "Hearing") to appeal the delisting process before a Nasdaq Heari

    2/27/26 4:30:00 PM ET
    $XTLB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris

    PARIS and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) --  NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that following the annual review of the Euronext Paris indices, the Scientific Council of the Indices has decided to admit Nanobiotix to both the CAC Mid 60 and SBF 120 indices. These changes will become effective after the market closes on Friday, December 19, 2025. The CAC Mid 60 and SBF 120 indices represent two of the most widely followed benchmarks for mid-sized and leading liste

    12/15/25 2:30:00 AM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer

    BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Marc J. Wolfgang, M.S. as Chief Technology Officer ("CTO"). Mr. Wolfgang brings more than 30 years of biopharmaceutical leadership spanning manufacturing, CMC strategy, development, quality, and supply chain across modalities including cell therapy, biologics, nucleic-acid medicines, vaccines, and LNP platforms. He most recently served as Senior Vice President of Technical Development and Operations at Sail Biomedicines (a Flagship

    11/19/25 8:00:00 AM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APDN
    $BPTS
    $DBVT
    $ELTX
    Financials

    Live finance-specific insights

    View All

    DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years

    Châtillon, France, December 16, 2025 DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years VITESSE met its primary endpoint: the lower bound of the 95% confidence interval (CI) of the difference between treatment arms was 24.5%, exceeding the prespecified threshold of 15% 46.6% of children treated with the VIASKIN® Peanut patch met response criteria at 12 months, compared to 14.8% of children in the placebo arm Safety results were consistent with the safety profile observed in the VIASKIN Peanut clinical program to dateBLA submission in 4-7-year-olds on track for the first half of 2026Achievement

    12/16/25 4:05:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Applied DNA Sciences to Begin Trading Under New Ticker 'BNBX' Reflecting Digital Asset Treasury Strategy

    Ticker changing from ‘APDN' to ‘BNBX' effective October 7, 2025 Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a biotechnology company advancing a yield focused BNB digital asset treasury strategy and commercializing nucleic acid production solutions, today announced that it will change its ticker symbol on the Nasdaq Capital Market ("Nasdaq") from "APDN" to "BNBX", effective at the opening of trading on Tuesday October 7, 2025. The ticker BNBX underscores the Company's strategic commitment to a BNB-based treasury strategy designed to optimize yield generation and token accumulation within the Binance ecosystem. The Company plans to implement a differentiated

    10/6/25 8:00:00 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1

    Data show a favorable safety profile and early efficacy signals in a heavily pre-treated population whose cancer progressed after multiple prior lines of therapy including anti-PD-1Recommended phase 2 dose (RP2D) established at 33% of gross tumor volume (GTV)47.4% (9/19) best observed objective response rate (ORR) in all lesions per RECIST 1.178.9% (15/19) best observed disease control rate (DCR) in all lesions per RECIST 1.114.6 months median Overall Survival (mOS) in all patients treated (n=21)Investigators concluded that these data warrant further investigation in randomized clinical trials as a potential new option for patients with primary cutaneous melanoma naïve or refractory to anti-

    9/17/25 4:15:00 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APDN
    $BPTS
    $DBVT
    $ELTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Molecular Templates Inc.

    SC 13G/A - Molecular Templates, Inc. (0001183765) (Subject)

    11/18/24 9:49:56 PM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Applied DNA Sciences Inc.

    SC 13G - APPLIED DNA SCIENCES INC (0000744452) (Subject)

    11/14/24 5:46:25 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Moleculin Biotech Inc.

    SC 13G/A - Moleculin Biotech, Inc. (0001659617) (Subject)

    11/14/24 5:12:06 PM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care